Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Leases: 2020-2024

Historic Capital Leases for Ptc Therapeutics (PTCT) over the last 5 years, with Dec 2024 value amounting to $15.6 million.

  • Ptc Therapeutics' Capital Leases fell 11.18% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 11.18%. This contributed to the annual value of $15.6 million for FY2024, which is 9.37% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Capital Leases is $15.6 million, which was down 9.37% from $17.2 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Capital Leases high stood at $23.1 million for FY2020, and its period low was $15.6 million during FY2024.
  • Moreover, its 3-year median value for Capital Leases was $17.2 million (2023), whereas its average is $17.1 million.
  • Data for Ptc Therapeutics' Capital Leases shows a maximum YoY declined of 12.99% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Capital Leases stood at $23.1 million in 2020, then declined by 12.99% to $20.1 million in 2021, then dropped by 7.09% to $18.7 million in 2022, then dropped by 7.98% to $17.2 million in 2023, then dropped by 9.37% to $15.6 million in 2024.